Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment

OBJECTIVE: Morbid obesity may be related to a prolactinoma, although uncommon, and can lead to adverse effects like insulin resistance and metabolic syndrome. Recent research suggests that hyperprolactinemia causes an abnormal lipid profile, weight gain, and cardiovascular diseases. Moreover, high p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Muzaffar, Mirza, Lubna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Clinical Endocrinology 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165126/
https://www.ncbi.nlm.nih.gov/pubmed/34095489
http://dx.doi.org/10.1016/j.aace.2021.01.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165126/
https://www.ncbi.nlm.nih.gov/pubmed/34095489
http://dx.doi.org/10.1016/j.aace.2021.01.004

Ejemplares similares